E-mails uncovered during the discovery process in the transvaginal mesh Multi-District Litigation in West Virginia reveal that executives at a subsidiary of CR Bard, Inc. knew that a plastic used in its transvaginal mesh product was unfit to use in humans due to the risk of erosion. CR Bard, Inc. and its subsidiaries manufactured a number of defective transvaginal mesh products that were implanted in women suffering from stress urinary incontinence and pelvic organ prolapse. The FDA estimates that in the year 2010 alone over 250,000 women were implanted with some form of transvaginal mesh.
According to the e-mails, managers in the Davol division of CR Bard continued to use a resin-based plastic in its transvaginal mesh products even after the plastic’s manufacturer, Chevron Phillips Chemical Co., filed documents with the federal government warning other manufacturers that the plastic should not be permanently implanted in humans. The managers went so far as to instruct other employees at Davol not to inform Chevron Phillips that the company was using the plastic in medical devices implanted in humans. The e-mails figure to play a key role in upcoming trials involving CR Bard’s transvaginal mesh products.
SUGARMAN principals Marianne LeBlanc and David McCormack continue to represent clients who have been implanted with defective or recalled transvaginal mesh products. If you believe you may be suffering from adverse medical complications as a result of a defective or recalled transvaginal mesh product, fill out a Contact Form, call Marianne LeBlanc or David McCormack at 617-542-1000 or e-mail Marianne LeBlanc or David McCormack.